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letter from the editor-in-chief
On behalf of the editorial board, it is my pleasure to introduce the first is-sue of Hematology/Oncology and Stem Cell Therapy. The core mission of this new journal is to provide a vehicle for publication of high quality 
clinical and basic research reports in hematology and oncology with a focus on 
manuscripts from countries whose research might be underrepresented in the 
current medical literature. The journal will publish high-quality articles that pass 
our rigorous peer review process. Priority will be given to manuscripts that have a 
greater public health impact or that highlight unique geographic distributions or 
behaviors of blood diseases or cancer. Additionally, the contents of the journal 
will reflect the growing importance of stem cell therapy in treating hematologic 
diseases and malignancies.
Members of the editorial board are from the Eastern Mediterranean region, 
Asia, Africa, Latin America, and Eastern Europe, thus providing adequate repre-
sentation from targeted geographic areas. The editorial board will follow a strict 
peer review and editorial process to ensure the objectivity, credibility and qual-
ity of the published material, and insist that authors adhere to ethical guidelines, 
disclose potential financial or other conflicts of interest, as well as follow uniform 
requirements for manuscript preparation as per international standards.
The journal will be published on a quarterly basis. However, if an adequate 
number of high quality research reports are received, the frequency of publica-
tion will be increased. The journal will be published electronically on an open 
access basis. Subsidized subscriptions for the print journal will be available for 
countries with a low per capita income to ensure adequate distribution of the 
journal to all targeted geographic areas.
The journal has a well-established web-based electronic system in place for 
submission, processing, and full-text retrieval of manuscripts for review and edit-
ing. We welcome any input from the readers or professional organizations in 
hematology and oncology in the targeted areas. I would like to thank the King 
Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia, for their 
generous support of this non-profit project. I look forward to receiving your input 
or suggestions to strengthen the mission of this journal.
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